用户登录转化医学是什么？

Empire Genomics完成收购美国 ID实验室

首页 » 产业 » 企业 2015-01-06 转化医学网赞(2)

导读	Empire Genomics公司周一表示，该公司已经收购了分子诊断试剂公司ID实验室，交易所涉金额尚未透露。

Empire Genomics公司周一表示，该公司已经收购了分子诊断试剂公司ID实验室，交易所涉金额尚未透露。

总部设在英国伦敦的安大略分子诊断试剂公司ID实验室为其在学术界、政府机构、制药企业、生物技术公司和各大医院的客户提供抗体、分子探针、遗传学细胞载体和其他分子生物学试剂。

Empire Genomics公司 CEO Anthony Johnson表示：“这笔交易与我们公司拓展临床实验室和客户产品业务的战略相一致，同时该项收购协议也能够增加我们的全球分销网络。”另外，Anthony Johnson同时强调该公司正在进行着对其他几家业内公司收购计划的拟定，进一步加快增长其在分子诊断领域业务的发展。

Empire Genomics (EG)开发并为患者提供全面的化验服务，对患者进行精确的诊断与科学的治疗指导，致力于满足病理学家、肿瘤学家和相关研究人员的各种研究和治疗需要。（转化医学网360zhyx.com）

以上为转化医学网原创翻译整理，谢绝转载。如需转载，请联系 info@360zhyx.com 。

转化医学网推荐的新闻阅读：

Empire Genomics said on Monday that it has acquired molecular diagnostic reagents firm ID Labs for an undisclosed amount.
Based in London, Ontario, ID Labs provides antibodies, molecular probes, cytogenetics media, and other molecular biology reagents to academia, government, pharmaceutical, biotech, and hospital customers.
Empire Genomics CEO Anthony Johnson said that the deal is aligned "with our corporate strategy of complementing the product offerings for our clinical lab and customers, as well as increasing our global distribution network." He added that he expects it to be the first of several acquisitions "as we look to accelerate the growth of our business in the ever changing molecular diagnostics environment."
Empire Genomics (EG) is a molecular diagnostics company that develops and offers a comprehensive menu of assay services for use in diagnosing and guiding precise therapeutic treatments for patients. The EG services are designed to specifically meet the needs of pathologists, oncologists and researchers.